CEO Interview: Novartis' Dan Vasella

Novartis has done better than most Pharmas over the past five years, though shareholders are still dissatisfied. But CEO Dan Vasella continues playing for the long-term -- pursuing R&D innovation and cost-effective dealmaking, all within a relatively conservative strategic framework.

By Roger Longman

All in all, it’s been a rough start to 2007 for Novartis AG’s flagship pharmaceutical division and the company’s chairman...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo